Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Squarepoint Ops LLC bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, HoldingsChannel.com reports. The fund bought 32,744 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,137,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANIP. Charles Schwab Investment Management Inc. boosted its holdings in ANI Pharmaceuticals by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after purchasing an additional 2,220 shares in the last quarter. Invesco Ltd. lifted its position in shares of ANI Pharmaceuticals by 1.0% during the 1st quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock worth $13,361,000 after buying an additional 2,022 shares during the period. Nuveen LLC acquired a new stake in ANI Pharmaceuticals in the 1st quarter valued at $3,254,000. Raymond James Financial Inc. boosted its stake in ANI Pharmaceuticals by 41.4% in the 1st quarter. Raymond James Financial Inc. now owns 100,164 shares of the specialty pharmaceutical company’s stock valued at $6,706,000 after buying an additional 29,338 shares in the last quarter. Finally, Northern Trust Corp grew its position in ANI Pharmaceuticals by 6.1% in the first quarter. Northern Trust Corp now owns 216,862 shares of the specialty pharmaceutical company’s stock valued at $14,519,000 after acquiring an additional 12,517 shares during the period. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other news, Director Patrick D. Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total value of $750,903.84. Following the completion of the sale, the director directly owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director directly owned 25,157 shares in the company, valued at $2,041,490.55. This trade represents a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 26,379 shares of company stock valued at $2,313,281 over the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:ANIP opened at $82.83 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The firm has a market cap of $1.86 billion, a P/E ratio of 50.82 and a beta of 0.48. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $99.50. The company’s 50-day moving average price is $86.84 and its two-hundred day moving average price is $81.20.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ANIP shares. Barclays started coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, September 24th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.14.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.